Abstract
Summary
The present observations indicate that alloxan is just as effective as a diabetogenic agent when given intrasplenically as when given subcutaneously. Similar amounts of alloxan given intraperitoneally result in many instances in a milder diabetes. It appears that alloxan is not inactivated specifically in the liver.
Get full access to this article
View all access options for this article.